LV12910B - Pharmaceutical composition comprising a combination of metformin and glibenclamide - Google Patents

Pharmaceutical composition comprising a combination of metformin and glibenclamide Download PDF

Info

Publication number
LV12910B
LV12910B LVP-02-94A LV020094A LV12910B LV 12910 B LV12910 B LV 12910B LV 020094 A LV020094 A LV 020094A LV 12910 B LV12910 B LV 12910B
Authority
LV
Latvia
Prior art keywords
metformin
glyburide
pharmaceutical composition
dose
combination
Prior art date
Application number
LVP-02-94A
Other languages
English (en)
Latvian (lv)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12910B publication Critical patent/LV12910B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-02-94A 1999-11-03 2002-06-03 Pharmaceutical composition comprising a combination of metformin and glibenclamide LV12910B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
LV12910B true LV12910B (en) 2003-05-20

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-94A LV12910B (en) 1999-11-03 2002-06-03 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Country Status (23)

Country Link
EP (1) EP1229918B1 (fr)
JP (1) JP5183844B2 (fr)
KR (1) KR20070089259A (fr)
CN (1) CN1450902A (fr)
AR (1) AR026356A1 (fr)
AT (1) ATE390140T1 (fr)
AU (1) AU780106B2 (fr)
BR (1) BR0015294A (fr)
CA (1) CA2389928C (fr)
EE (1) EE05260B1 (fr)
HU (1) HU229352B1 (fr)
IL (1) IL149139A0 (fr)
LT (1) LT5058B (fr)
LV (1) LV12910B (fr)
MX (1) MXPA02004282A (fr)
NO (1) NO330026B1 (fr)
NZ (1) NZ518278A (fr)
PL (1) PL199278B1 (fr)
RU (1) RU2275915C2 (fr)
SK (1) SK287810B6 (fr)
TW (1) TWI280125B (fr)
UY (1) UY26424A1 (fr)
WO (1) WO2001032157A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (fr) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformine utilisee dans le traitement de conditions hyperglycemiques
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003105809A1 (fr) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Comprimes multicouche contenant des thiazolidinediones et des biguanides et procedes de production desdits comprimes
EP1680115A1 (fr) * 2003-10-30 2006-07-19 Tioga Pharmaceuticals, Inc. Utilisation de modulateurs selectifs des recepteurs des opiaces en traitement d'une neuropathie
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
AU2005240122B2 (en) * 2004-05-03 2011-02-17 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
EP2185138B1 (fr) 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Preparation solide comprenant du alogliptin et metformin chlorhydrate
EA020209B1 (ru) 2007-09-10 2014-09-30 Янссен Фармацевтика Н.В. Способ получения соединений, применимых в качестве ингибиторов натрийзависимого переносчика глюкозы
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
WO2011058082A1 (fr) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1 et de la méthionine
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
TW201236692A (en) * 2011-02-02 2012-09-16 Sanofi Aventis Deutschland Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
WO1998057634A1 (fr) 1997-06-18 1998-12-23 Smithkline Beecham Plc Traitement du diabete a l'aide de thiazolidinedione et de metformine
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
EP0974356B1 (fr) * 1998-07-15 2003-09-24 Merck Sante Comprimés contenant une combinaison de glibenclamide et de metformine
EP2620443A1 (fr) 2012-01-25 2013-07-31 Galecto Biotech AB Nouveaux inhibiteurs de galectines au galactoside

Also Published As

Publication number Publication date
HUP0300218A3 (en) 2006-02-28
AR026356A1 (es) 2003-02-05
KR20070089259A (ko) 2007-08-30
RU2002114820A (ru) 2004-03-10
IL149139A0 (en) 2002-11-10
AU1082601A (en) 2001-05-14
ATE390140T1 (de) 2008-04-15
CA2389928A1 (fr) 2001-05-10
JP5183844B2 (ja) 2013-04-17
EP1229918A2 (fr) 2002-08-14
CA2389928C (fr) 2010-03-23
BR0015294A (pt) 2003-07-15
HU229352B1 (en) 2013-11-28
AU780106B2 (en) 2005-03-03
NO330026B1 (no) 2011-02-07
TWI280125B (en) 2007-05-01
RU2275915C2 (ru) 2006-05-10
WO2001032157A2 (fr) 2001-05-10
NO20022087D0 (no) 2002-05-02
SK5002002A3 (en) 2004-05-04
UY26424A1 (es) 2001-05-31
EP1229918B1 (fr) 2008-03-26
NO20022087L (no) 2002-06-24
PL199278B1 (pl) 2008-09-30
LT5058B (lt) 2003-09-25
EE200200242A (et) 2003-12-15
LT2002063A (en) 2003-06-25
EE05260B1 (et) 2010-02-15
HUP0300218A2 (hu) 2003-06-28
NZ518278A (en) 2004-10-29
MXPA02004282A (es) 2003-02-17
WO2001032157A3 (fr) 2002-01-24
CN1450902A (zh) 2003-10-22
PL364885A1 (en) 2004-12-27
JP2003519621A (ja) 2003-06-24
SK287810B6 (sk) 2011-10-04

Similar Documents

Publication Publication Date Title
US7598262B2 (en) Method for treating diabetes
EP1229918B1 (fr) Composition pharmaceutique comprenant une combinaison de metformine et de glibenclamide
US7507768B2 (en) Antidiabetic formulation and method
JP2003519621A5 (fr)
AU8022900B2 (fr)
AU2002357095B2 (en) Antidiabetic formulation and method